PeriFlow Therapeutics develops highly-specific myosin inhibitors
to relieve pathological “hypercontractions”
CLN-2501 / Ischemia Program
Skeletal Muscle Program
CLN-2501 is a first-in-class Capillary-Selective Vasodilator. CLN-2501 restores capillary flow in acute myocardial infarction, acute kidney injury, stroke and organ transplant.
Skeletal muscle myosin inhibitors relax muscle spasticity after neurological injuries such as stroke, MS, ALS, and Stiff Person Syndrome. Skeletal muscle myosin inhibitors also calm tremors in epilepsy, essential tremor, and other conditions.
Targeting specific myosin proteins
to resolve pathological
“hypercontractions”
at the effector site.
PeriFlow is the only biotech company that is advancing development-stage smooth muscle myosin inhibitors.
Our lead asset, CLN-2501, binds to smooth muscle in the capillaries of the heart.
PeriFlow‘s portfolio includes inhibitors of myosin targets that have only recently become druggable.
PeriFlow has the broadest tool-kit of myosin proteins to support efficient drug development.
PeriFlow licenses, develops and commercializes drug innovations from Motorpharma Kft, one of the world’s leading myosin biology labs, in Budapest, Hungary.
Contact us
info@periflowtx.com
1 Broadway, 14th floor
Cambridge, MA 02142